Tigecycline Use in Pneumonia Treatment
Evidence Against Tigecycline Use
- Tigecycline should not be used for the treatment of pneumonia in patients with COPD due to higher mortality rates and treatment failure compared to alternative therapies 1
- Clinical guidelines note "no experience in pneumonia for tigecycline" when discussing treatment options for various pathogens in pneumonia 2, 3
- Tigecycline monotherapy has demonstrated higher rates of treatment failure compared to alternative therapies for respiratory infections 1
Recommended First-Line Treatments for Pneumonia in COPD
- The European Respiratory Society recommends aminopenicillin ± macrolide, aminopenicillin/β-lactamase inhibitor ± macrolide, non-antipseudomonal cephalosporin (cefotaxime or ceftriaxone) ± macrolide, levofloxacin or moxifloxacin, and penicillin G ± macrolide as first-line treatments for pneumonia in COPD patients 2
- For hospitalized patients with community-acquired pneumonia in COPD, the above options are recommended in alphabetical order 2, 3
Special Considerations for COPD Patients
- The Global Initiative for Chronic Obstructive Lung Disease recommends antibiotics in exacerbations of COPD when patients present with increased dyspnea, increased sputum volume, and increased sputum purulence 4
- The European Respiratory Society suggests considering antibiotics for exacerbations in patients with severe COPD, even if they don't have all three symptoms 4
- First-choice antibiotics for COPD patients include amoxicillin or tetracycline based on least chance of harm and wide clinical experience 5
- In case of hypersensitivity, a tetracycline or macrolide such as azithromycin, clarithromycin, erythromycin, or roxithromycin is recommended in areas with low pneumococcal macrolide resistance 5